<DOC>
	<DOC>NCT02319486</DOC>
	<brief_summary>This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma</brief_summary>
	<brief_title>CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma</brief_title>
	<detailed_description>This study will be a phase 4 open label interventional case series. Patients with retinoblastoma will be receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive chemotherapy on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 18 months .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>IRSS stage II or stage IIIa RB patients. for patients with IRSS stage II disease, if scleral surface invasion alone was observed, only systemic chemotherapy was administered, whereas other IRSS stage II and IIIa patients received systemic chemotherapy plus additional local chemotherapy. no tumorrelated treatment was given prior to this chemotherapy regimen. metastasis, including lymph node metastasis. the diagnosis of IRSS stage I or above in the nontarget eye.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Retinoblastoma</keyword>
	<keyword>carboplatin</keyword>
</DOC>